Common Contracts
3 similar Research Collaboration and License Agreement contracts by Iambic Therapeutics, Inc.
RESEARCH COLLABORATION AND LICENSE AGREEMENT DATED AS OF FEBRUARY 3, 2026 BY AND BETWEEN IAMBIC THERAPEUTICS, INC. AND TAKEDA PHARMACEUTICALS, U.S.A., INC.Research Collaboration and License Agreement • September 21st, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Research Collaboration and License Agreement (this “Agreement”), effective as of February 3, 2026 (the “Effective Date”), is entered into by and between Takeda Pharmaceuticals U.S.A., Inc., a corporation organized under the laws of the State of Delaware (“Takeda”), and Iambic Therapeutics, Inc., a Delaware corporation having a place of business at 5627 Oberlin Drive, Suite 120, San Diego, California, 92121 (“Iambic”). Takeda and Iambic are referred to individually as a “Party” and collectively as the “Parties.”
RESEARCH COLLABORATION AND LICENSE AGREEMENT DATED AS OF FEBRUARY 3, 2026 BY AND BETWEEN IAMBIC THERAPEUTICS, INC. AND TAKEDA PHARMACEUTICALS, U.S.A., INC.Research Collaboration and License Agreement • August 28th, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Research Collaboration and License Agreement (this “Agreement”), effective as of February 3, 2026 (the “Effective Date”), is entered into by and between Takeda Pharmaceuticals U.S.A., Inc., a corporation organized under the laws of the State of Delaware (“Takeda”), and Iambic Therapeutics, Inc., a Delaware corporation having a place of business at 5627 Oberlin Drive, Suite 120, San Diego, California, 92121 (“Iambic”). Takeda and Iambic are referred to individually as a “Party” and collectively as the “Parties.”
RESEARCH COLLABORATION AND LICENSE AGREEMENT DATED AS OF FEBRUARY 3, 2026 BY AND BETWEEN IAMBIC THERAPEUTICS, INC. AND TAKEDA PHARMACEUTICALS, U.S.A., INC.Research Collaboration and License Agreement • July 24th, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Research Collaboration and License Agreement (this “Agreement”), effective as of February 3, 2026 (the “Effective Date”), is entered into by and between Takeda Pharmaceuticals U.S.A., Inc., a corporation organized under the laws of the State of Delaware (“Takeda”), and Iambic Therapeutics, Inc., a Delaware corporation having a place of business at 5627 Oberlin Drive, Suite 120, San Diego, California, 92121 (“Iambic”). Takeda and Iambic are referred to individually as a “Party” and collectively as the “Parties.”